By Measuring The Ability To Specifically Bind A Target Molecule (e.g., Antibody-antigen Binding, Receptor-ligand Binding, Etc.) Patents (Class 506/9)
  • Patent number: 11946099
    Abstract: The invention comprises a method of amplifying nucleic acids by primer extension with reduced formation of primer-primer byproducts.
    Type: Grant
    Filed: February 23, 2021
    Date of Patent: April 2, 2024
    Inventor: Brian Godwin
  • Patent number: 11913062
    Abstract: Present disclosure provides a method including isolating DNA from a source, thereby providing a composition including the isolated DNA. The isolated DNA has at least first and second target regions, where the length of the second target region is greater than the length of the first target region. The method further includes quantifying a total mass of the isolated DNA, quantifying a first quantification cycle (Cq) of the first target region and a second Cq of the second target region, and calculating a Q-ratio for the isolated DNA by dividing the second Cq by the first Cq. The method further includes determining a value for a quality-mass constant (kQm), estimating a required input mass by dividing kQm by the Q-ratio, and preparing the isolated DNA for sequencing if the total mass of the isolated DNA in the composition is equal or greater than the required input mass.
    Type: Grant
    Filed: November 18, 2019
    Date of Patent: February 27, 2024
    Assignees: Roche Sequencing Solutions, Inc., Signature Diagnostics GmbH
    Inventors: Victoria Constandse, Daniel Klass, Alexander Lovejoy, Melissa Loyzer, Bronwen Miller, Bernd Hinzmann, Sophie Beckert
  • Patent number: 11908588
    Abstract: Contemplated systems and methods use identification and classification of somatic single nucleotide variants found in a primary tumor and metastases to determine phylogeny of the metastases.
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: February 20, 2024
    Assignee: NantOmics LLC
    Inventor: John Zachary Sanborn
  • Patent number: 11873482
    Abstract: Provided herein are methods for capturing a connected probe and/or a capture handle sequence to a capture domain of a capture probe.
    Type: Grant
    Filed: April 27, 2023
    Date of Patent: January 16, 2024
    Assignee: 10x Genomics, Inc.
    Inventors: Hanyoup Kim, David Sukovich, Layla Katiraee, Augusto Manuel Tentori, Lauren Gutgesell, Janine Hensel, Seayar Mohabbat
  • Patent number: 11874279
    Abstract: Arrays of single molecules and methods of producing an array of single molecules are described. Arrays with defined volumes between 10 attoliters and 50 picoliters enable single molecule detection and quantitation.
    Type: Grant
    Filed: October 8, 2021
    Date of Patent: January 16, 2024
    Assignee: Trustees of Tufts College
    Inventors: David R. Walt, David M. Rissin
  • Patent number: 11866771
    Abstract: System, including methods, apparatus, compositions, and kits, for making and using a stabilized emulsion. A method of generating a stabilized emulsion is provided. In the method, an aqueous phase may be provided. The aqueous phase may include an effective concentration of one or more skin-forming proteins. An emulsion may be formed. The emulsion may include droplets of a dispersed phase disposed in a continuous phase, with the aqueous phase being the continuous phase or the dispersed phase. The emulsion may be heated to create an interfacial skin between each droplet and the continuous phase, to transform the droplets into capsules.
    Type: Grant
    Filed: June 11, 2021
    Date of Patent: January 9, 2024
    Assignee: Bio-Rad Laboratories, Inc.
    Inventors: Amy L. Hiddessen, Benjamin J. Hindson
  • Patent number: 11859254
    Abstract: Provided herein is technology relating to detecting neoplasia and particularly, but not exclusively, to methods, compositions, and related uses for detecting premalignant and malignant neoplasms such as gastric cancer.
    Type: Grant
    Filed: February 5, 2020
    Date of Patent: January 2, 2024
    Inventors: David A. Ahlquist, William R. Taylor, John B. Kisiel, Tracy C. Yab, Douglas W. Mahoney, Hatim T. Allawi
  • Patent number: 11836998
    Abstract: A method of predicting cancer recurrence risk for an individual includes receiving patient spatial multi-parameter cellular and sub-cellular imaging data for a tumor of the individual, and analyzing the patient spatial multi-parameter cellular and sub-cellular imaging data using a prognostic model for predicting cancer recurrence risk to determine a predicted cancer recurrence risk for the individual, wherein the joint prognostic model is based on spatial correlation statistics among features derived for a plurality of intra-tumor spatial domains from spatial multi-parameter cellular and sub-cellular imaging data obtained from a plurality of cancer patients.
    Type: Grant
    Filed: May 23, 2019
    Date of Patent: December 5, 2023
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Srinivas C. Chennubhotla, Douglass L. Taylor, Shikhar Uttam Fnu
  • Patent number: 11827934
    Abstract: Compositions, methods and systems are provided for isolating nucleic acids. A polymerase-nucleic acid complex can be formed by mixing a polymerase enzyme comprising strand displacement activity and a mixture of double stranded nucleic acids. Nucleic acid synthesis can then be initiated by the polymerase enzyme to produce a nascent strand complementary to the first strand, thereby displacing a portion of the second strand. After halting or reducing the rate of nucleic acid synthesis, a hybridizing a hook oligonucleotide can be used hybridize to the nucleic acid through a capture region on the hook oligonucleotide that is complementary to the displaced portion of the second strand. The nucleic acid can then be isolated from the mixture of nucleic acids using the hook oligonucleotide.
    Type: Grant
    Filed: February 26, 2021
    Date of Patent: November 28, 2023
    Assignee: Pacific Biosciences of California, Inc.
    Inventors: Thang Pham, Arunashree Bhamidipati, Kevin Travers, Eric Olivares, Tyson A. Clark, Jonas Korlach
  • Patent number: 11827922
    Abstract: Methods of profiling the nucleic acid composition of single cells and tools for same. The methods can include isolating a single cell in a liquid droplet, lysing the single cell in the liquid droplet to release template nucleic acid from the cell, amplifying the template nucleic acid in the liquid droplet to generate amplified nucleic acid, and detecting the amplified nucleic acid in the liquid droplet. The methods can be useful for profiling expression patterns and/or detecting genetic characteristics such as single nucleotide polymorphisms. The tools include nucleic acid logic gates, including polymerase-dependent logic gates. The logic gates can perform logical operations such as YES, NOT, AND, OR, AND-NOT, NOT-AND, NOT-OR, EXCLUSIVE-OR, EXCLUSIVE-NOR, and IMPLY. The tools also include microfluidic systems for performing the methods.
    Type: Grant
    Filed: March 6, 2019
    Date of Patent: November 28, 2023
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Philip Anthony Romero, Leland Bradford Hyman
  • Patent number: 11802874
    Abstract: The present invention corresponds to the field of cancer and is related to predicting cancer detection, diagnosis, monitoring and prediction of response to treatment, in particular platelet derived-endothelial cell growth factor (PD-ECGF) levels for their use as a potential value in monitoring disease evolution and predicting response to anti-angiogenic treatment.
    Type: Grant
    Filed: March 10, 2016
    Date of Patent: October 31, 2023
    Inventors: Oriol Casanovas Casanovas, Gabriela Jiménez Valerio, María Ochoa De Olza, Valentí Navarro Pérez, Nicklas Bassani, Helena Verdaguer
  • Patent number: 11795304
    Abstract: The present invention provides an improved method of quantitative and/or qualitative analysis of a target molecule using nitrocellulose membrane (NCM). In particular, the present invention provides a porous nitrocellulose membrane that includes a surface and an organic nanostructured molecule that is non-covalently attached to the surface of NCM. The organic nanostructured molecule has a branched region that includes a plurality of terminal region (e.g., terminal end) moieties that are non-covalently attached or bound to a surface of the porous NCM. The organic nanostructured molecule also comprises a linear region that includes a covalently attached capture molecule that is adapted to selectively bind to a target molecule. The NCM of the invention provides an improved reproducibility, reliability, and selectivity compared an NCM in the absence of the organic nanostructured molecule.
    Type: Grant
    Filed: November 1, 2018
    Date of Patent: October 24, 2023
    Assignee: NB Postech
    Inventors: Joon Won Park, Sung Min Seo
  • Patent number: 11796472
    Abstract: The present technology is directed to the nanoparticles for use as molecular environmental sensors. The nanoparticles comprise a photoluminescence core and a plurality of ligands bound to the core and forming a quencher permeable ligand shell. The ligands comprise a reactive or charged moiety capable of being modulated between a first stand and a second state, and the proportion of ligands in each state determine the permeability of the ligand shell to a photoluminescence quencher.
    Type: Grant
    Filed: October 19, 2021
    Date of Patent: October 24, 2023
    Assignee: Northwestern University
    Inventors: Chen He, David J. Weinberg, Emily A. Weiss, Jeremiah Yoonsung Kim, Chen Wang, Andrew Lee
  • Patent number: 11795579
    Abstract: Compositions and methods for displaying antibodies in the periplasmic space of yeast cells are disclosed. In particular, antibodies are linked to a cell membrane-spanning transmembrane domain, a cell-membrane associated protein domain that is on the external face of the yeast cell membrane, a protein that binds to the inner face of the yeast cell wall, or a periplasmic protein in order to display the antibodies in the yeast periplasmic space. In addition, a target protein of interest can be coexpressed in yeast such that it is localized to the plasma membrane or periplasmic space and accessible to binding by displayed antibodies. The disclosure further relates to high-throughput screening of antibody libraries using yeast cell periplasmic display.
    Type: Grant
    Filed: December 10, 2018
    Date of Patent: October 24, 2023
    Assignee: Abalone Bio, Inc.
    Inventors: Richard Yu, Carlos Gustavo Pesce, Rodrigo Baltanas, Brett Robison
  • Patent number: 11779897
    Abstract: An example of a flow cell includes a substrate, a plurality of chambers defined on or in the substrate, and a plurality of depressions defined in the substrate and within a perimeter of each of the plurality of chambers. The depressions are separated by interstitial regions. Primers are attached within each of the plurality of depressions, and a capture site is located within each of the plurality of chambers.
    Type: Grant
    Filed: October 31, 2021
    Date of Patent: October 10, 2023
    Assignee: Illumina, Inc.
    Inventors: Lewis J. Kraft, Tarun Kumar Khurana, Yir-Shyuan Wu, Xi-Jun Chen, Arnaud Rival, Justin Fullerton, M. Shane Bowen, Hui Han, Jeffrey S. Fisher, Yasaman Farshchi, Mathieu Lessard-Viger
  • Patent number: 11774446
    Abstract: Provided herein are methods, assays and devices for the detection and diagnosis of autoimmune diseases, including systemic lupus erythematosus. The methods, assays and devices provided herein analyzes binding patterns of peripheral-blood antibodies on peptide array that correlates well with current systemic lupus erythematosus clinical assessment standards.
    Type: Grant
    Filed: June 20, 2017
    Date of Patent: October 3, 2023
    Inventors: Michael William Rowe, Theodore Michael Tarasow, Jonathan Scott Melnick
  • Patent number: 11774457
    Abstract: Protein biomarkers may be used to rapidly and accurately diagnose stroke. Biomarkers may be utilized in a rapid and inexpensive test that could be used at the bedside or ambulatory setting to definitively indicate the presence or absence of stroke and its severity. Such a test would quickly stratify patients in need of immediate stroke treatment from those who are not having a stroke. The test may aid emergency personnel in the decision for the most appropriate treatment plan and treatment location, thereby minimizing morbidity and mortality of stroke patients.
    Type: Grant
    Filed: July 9, 2019
    Date of Patent: October 3, 2023
    Assignee: Wright State University
    Inventors: James Edwin Olson, April Daubenspeck, David Cool, Bryan Ludwig
  • Patent number: 11774455
    Abstract: A peptide aptamer for specific recognition of arginine and its application are provided. The sequence of the peptide aptamer is shown in SEQ ID No. 1. The peptide aptamer is modified by a group that improves stability, or by a fluorescent group, an isotope and an electrochemical group that provide a detection signal, or by an affinity ligand and a mercapto. According to the computer-aided molecular docking simulation prediction, the peptide aptamer that can specifically bind to L-arginine is screened, which is verified by an isothermal titration calorimeter. The peptide aptamer has the advantages of good stability, strong binding ability, high specificity and low production cost.
    Type: Grant
    Filed: November 16, 2019
    Date of Patent: October 3, 2023
    Inventors: Zemeng Feng, Yumin He, Lei Deng, Zhong Cao, Zhongliang Xiao, Yulong Yin
  • Patent number: 11774460
    Abstract: Provided herein is a method of detecting or predicting a relapse of multiple sclerosis in an individual afflicted with a form of multiple sclerosis, comprising: (a) providing a blood sample of the individual; (b) testing the blood sample to determine a protein activity or protein level, wherein the protein is Factor VIII, von Willebrand factor, or Protein C; and (c) detecting or predicting a relapse of multiple sclerosis in the individual if the protein activity or protein level is elevated compared to the protein activity or protein level in an individual not afflicted with the form of multiple sclerosis and patients' own baseline values. Also provided herein is a method of treating an individual afflicted with multiple sclerosis, who is experiencing a relapse or predicted to experience a relapse, comprising treating the individual by administering a dose of a steroid or anti-coagulation compound effective to alleviate the symptom of multiple sclerosis.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: October 3, 2023
    Assignee: Dignity Health
    Inventor: Dolly Roy
  • Patent number: 11768203
    Abstract: Provided herein are methods for detecting an antigen or for detecting expression of a chimeric antigen receptor (CAR). The methods include obtaining a sample from a subject, contacting the sample with a fusion protein comprising a reporter fused to a single chain antibody specific to the antigen or fused to an extracellular domain of an antigen targeted by the CAR or fused to Protein L and assaying the activity of the reporter, wherein presence of reporter activity or increase in reporter activity relative to a reference value is indicative of presence of the antigen or presence of the expression of the chimeric antigen receptor in the sample.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: September 26, 2023
    Assignee: University of Southern California
    Inventor: Preet M. Chaudhary
  • Patent number: 11753626
    Abstract: Provided are suspension-based cell culture systems and media for the timely and efficient proliferation of human tumor cell clusters from a patient, and related methods of evaluating the potential responsiveness of the tumor cells and the patient to one or more therapeutic agents.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: September 12, 2023
    Inventors: Yiyou Chen, Zhen Yang, Yihong Zhang
  • Patent number: 11747334
    Abstract: Provided herein are methods, assays and devices for the differential diagnosis and detection of disease progression of autoimmune diseases. The methods, assays and devices provided herein produce and analyze binding patterns of peripheral-blood antibodies on mimetic peptide arrays that differentiate autoimmune diseases, and identify patients progressing to internal organ complications such as interstitial lung disease (ILD), and gastric antral vascular ectasia (GAVE), or renal involvement.
    Type: Grant
    Filed: June 20, 2017
    Date of Patent: September 5, 2023
    Inventors: Robert William Gerwien, Theodore Michael Tarasow, Jonathan Scott Melnick
  • Patent number: 11740226
    Abstract: Embodiments of the disclosure provide various nanogap sensor designs (e.g., horizontal nanogap sensors, vertical nanogap sensors, arrays of multiple nanogap sensors, various arrangements for making electrical connections to the electrodes of nanogap sensors, etc.), as well as various methods which may be used to fabricate at least some of the proposed sensors. The nanogap sensors proposed herein may operate as molecular sensors to help identify chemical species through electrical measurements using at least a pair of electrodes separated by a nanogap.
    Type: Grant
    Filed: October 8, 2018
    Date of Patent: August 29, 2023
    Inventors: Christophe Antoine, Himanshu Jain, Matthew Thomas Canty, Christina B. McLoughlin, Daniel Joseph Lucey, Sinead Maire McDermott, Stephen O'Brien, Bernard Stenson, Shane Geary, William Allan Lane, Michael Coln, Mark De Leon Alea
  • Patent number: 11730819
    Abstract: A compound comprising at least one looped peptide structure attached via at least one alkylamino linkage to a scaffold. Preferably the looped peptide structure is a Bicycle structure comprising two peptide loops attached to the scaffold via two alkylamino linkages and one thioether linkage, one of the linkages being common to both loops.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: August 22, 2023
    Assignee: BicycleTx Limited
    Inventors: Daniel Teufel, Gemma Mudd, Silvia Pavan
  • Patent number: 11733251
    Abstract: Methods and systems of performing an assay. A system for performing an assay includes an enclosure defining a temperature-controlled space. An imaging system, an actuator and a dispenser are disposed within the space. The actuator receives a well plate having wells. The actuator is to move the well plate relative to the imaging system to enable the imaging system to obtain image data of one of the wells. The dispenser includes a pump, an outlet and a reservoir holder to receive a reservoir containing a compound. The pump is to be fluidly coupled to the reservoir and an outlet. The pump is to pump the compound from the reservoir through the outlet into one of the wells. The system also includes a controller. The controller is to cause the dispenser to dispense the compound into the first one of the wells while the imaging system obtains the image data.
    Type: Grant
    Filed: January 14, 2020
    Date of Patent: August 22, 2023
    Assignee: AMGEN INC.
    Inventors: Brandon Zachary Sarich, Michael R. Berke, Chuck Z. Li, Thomas Clark Pearson
  • Patent number: 11732303
    Abstract: The present inventors identified for the first time a germline genomic alteration that accounts for familial myeloproliferative neoplasms (MPN) and myeloid malignancies. More precisely, they identified a 700 kb germline duplication that proposes patients to essential thrombocythemia (ET) with a high frequency of evolution to myelofibrosis (MF), secondary myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML). Two out of the 6 duplicated genes (namely ATG2B and GSKIP) have been shown to be overexpressed in hematopoietic progenitors, and this overexpression cooperates with classical mutations in JAK2, MPL, and CALR to generate the MPN phenotype. The presence of the 700 kb germline duplication is thus of poor prognosis for a MPN patient. The present invention discloses a method for detecting a predisposition of developing a MPN, as well as a prognostic method for assessing the probability that an ET-suffering patient will develop a myelofibrosis, a secondary MDS or an AML.
    Type: Grant
    Filed: June 24, 2016
    Date of Patent: August 22, 2023
    Assignee: Institut Gustave-Roussy
    Inventors: Christine Bellane-Chantelot, Isabelle Plo, William Vainchenker, Cécile Saint-Martin, Antonio D Di Stefano, Joseph Saliba
  • Patent number: 11705939
    Abstract: A dual cavity, low power, outdoor combination line amplifier package for cable telecommunication systems is disclosed. It comprises: a dual-cavity main frame, cast in one piece and sectioned into an upper cavity and a lower cavity; a hardline entry cover, having a hardline receptacle PCB with a power supply fixed thereon, electrically and environmentally sealing on one side of the upper cavity; a tap plate cover, having a tap plate PCB fixed thereon and mounted with a plurality of taps, electrically and environmentally sealing on the other side of the upper cavity with the taps facing externally; a gain module heatsink cover, having a gain module PCB and a passive PCB fixed thereon, electrically and environmentally sealing on one side of the lower cavity; and a smart app accessories cover, having a smart access cover PCB fixed thereon, electrically and environmentally sealing on the other side of the lower cavity.
    Type: Grant
    Filed: January 28, 2022
    Date of Patent: July 18, 2023
    Assignees: SANMU LTD., 3MU LLC
    Inventor: Donald Charles Dove
  • Patent number: 11704808
    Abstract: A segmentation method for tumor regions in a pathological image of clear cell renal cell carcinoma based on deep learning includes data acquisition and pre-processing, building and training of a classification network SENet and prediction of tumor regions. The present invention studies clear cell renal cell carcinoma based on pathological images, yielding results with higher reliability than judgments made based on CT or MRI images. The present invention overcomes the drawback that the previous research on clear cell renal cell carcinoma is only limited to judgment on presence by being able to visually provide the position and size of tumor regions, which is convenient for the medical profession to better study the pathogenesis and directions to the treatment of clear cell renal cell carcinoma.
    Type: Grant
    Filed: February 23, 2023
    Date of Patent: July 18, 2023
    Inventors: Ninghan Feng, Hong Tang, Guanzhen Yu, Jinzhu Su, Yang Wang, Yangkun Feng, Peng Jiang
  • Patent number: 11702697
    Abstract: The present invention provides method essentially comprising the steps of (i) providing a DNA sample, (ii) providing at least a first pair of amplification primers which is capable of generating a first amplicon from a LINE sequence that has a size of less than 80 bp, (iii) providing at least a second pair of amplification primers which is capable of generating a second amplicon from a LINE sequence that has a size of more than 160 bp, (iv) performing a qPCR and determining cq values for each of the generated amplicons, and (v) determining the relative concentrations of said amplicons.
    Type: Grant
    Filed: May 14, 2018
    Date of Patent: July 18, 2023
    Assignee: Roche Sequencing Solutions, Inc.
    Inventors: Sophie Beckert, Bernd Hinzmann
  • Patent number: 11705219
    Abstract: The technology disclosed directly operates on sequencing data and derives its own feature filters. It processes a plurality of aligned reads that span a target base position. It combines elegant encoding of the reads with a lightweight analysis to produce good recall and precision using lightweight hardware. For instance, one million training examples of target base variant sites with 50 to 100 reads each can be trained on a single GPU card in less than 10 hours with good recall and precision. A single GPU card is desirable because it a computer with a single GPU is inexpensive, almost universally within reach for users looking at genetic data. It is readily available on could-based platforms.
    Type: Grant
    Filed: January 14, 2019
    Date of Patent: July 18, 2023
    Assignees: Illumina, Inc., Illumina Cambridge Limited
    Inventors: Ole Schulz-Trieglaff, Anthony James Cox, Kai-How Farh
  • Patent number: 11705226
    Abstract: A method and system for storing user application programs and micro-service programs, for each of multiple patients that have cancerous cells and receive treatment, includes obtaining clinical records data in original forms, storing it in a semi-structured first database, generating sequencing data for the patient's cancerous and normal cells using a next generation genomic sequencer, storing the sequencing data in the first database, shaping at least some of the first database data to generate system structured data optimized for searching and including clinical record data, storing the structured data in a second database, for each user application program, selecting an application-specific subset of data from the second database and storing it in a structure optimized for application program interfacing in a third database, wherein an orchestration manager operatively connected to one or more micro-service programs receives status messages and initiates a respective micro-service program when program prere
    Type: Grant
    Filed: October 18, 2019
    Date of Patent: July 18, 2023
    Assignee: Tempus Labs, Inc.
    Inventors: Shane Colley, Isaiah Simpson, Brian Reuter, Robert Tell, Hailey Lefkofsky, Hunter Lane, Kevin White, Nike Beaubier, Stephen Bush, Aly Khan, Denise Lau, Kaanan Shah, Eric Lefkofsky
  • Patent number: 11690361
    Abstract: Applicants have identified that three critical phenotypic/genetic measures are highly correlated with transition period health and may be used in selection and breeding protocols and/or in combination with traditional breeding and marker assisted selection methods to improve predictability of transition period health. According to the invention genetic evaluations for mastitis, ketosis, and metritis have been found to be highly predictive of overall transition health. The genetic evaluations are produced by directly measuring thousands of clinical cases of mastitis, ketosis, and metritis in ancestors of a particular animal and using this data in selection. Applicant's selection criteria and quickly impact a breeders population by reducing transition cow disease incidence in the initial population and in progeny.
    Type: Grant
    Filed: June 19, 2019
    Date of Patent: July 4, 2023
    Assignee: ABS Global, Inc.
    Inventors: Katrina Dattilo, Yalda Zare, Gabriela Marquez Betz, Kaleena Stephan, Ryan Starkenburg, Cristian Vergara
  • Patent number: 11680296
    Abstract: Gene expression signatures and pathways associated with tuberculosis are identified. The invention provides for diagnostic assays based on gene markers and cell composition, as well as therapeutic targets for modulating tuberculosis infection. In addition, tuberculosis copy number contained in cells and methods of detecting high and low copy number are disclosed.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: June 20, 2023
    Assignee: Massachusetts Institute of Technology
    Inventors: Alexander K. Shalek, Carly Ziegler
  • Patent number: 11673966
    Abstract: The present invention discloses a mouse-human chimeric antibody preferably recognizes the MUC1 glycopeptide epitope RPAPGS(GalNAc)TAPPAHG (SEQ ID NO.: 34) on the surface of cancer cells, and the encoding sequences, wherein the monoclonal antibody having a light chain and a heavy chain. Moreover, the present invention provides humanized light and heavy chains, and the encoding sequences. The results of paired expression show that humanized antibodies also recognize the MUC1 glycopeptide epitope RPAPGS(GalNAc)TAPPAHG (SEQ ID NO.: 34) on the surface of cancer cells, and show the same specificity as the parental antibody.
    Type: Grant
    Filed: January 18, 2017
    Date of Patent: June 13, 2023
    Assignees: NanoCruise Pharmaceutical Ltd., Board of Regents of The University of Texas System
    Inventors: Dapeng Zhou, Patrick Hwu
  • Patent number: 11674182
    Abstract: The present invention provides MEL-18, which is a biomarker for human epidermal growth factor receptor2 (HER2)-positive cancer and anti-HER2 therapy, and a use thereof. According to the present invention, MEL-18 is a prognostic factor or predictor for a response of subjects to an anti-HER2-targeted drug in HER2-POSITIVE cancer and may be used in companion diagnostics for HER2-targeted drugs in subjects with HER2-positive cancer. Therefore, HER2-positive cancer may be more effectively treated by overcoming resistance to HER2 therapeutic agents and enhancing therapeutic efficacy by determining whether ADAM10/17 inhibitors are administered or co-administered with HER2-targeted drugs.
    Type: Grant
    Filed: March 8, 2018
    Date of Patent: June 13, 2023
    Inventors: Gu Kong, Jeong-Yeon Lee, Hyeong-Seok Joo
  • Patent number: 11670400
    Abstract: Methods, systems, and apparatus, including computer programs encoded on computer storage media, for obtaining data defining a sequence for an aptamer, the aptamer comprising a string of nucleobases; encoding the data defining the sequence for the aptamer as a neural network input; and processing the neural network input using a neural network to generate an output that characterizes how strongly the aptamer binds to a particular target molecule, wherein the neural network has been configured through training to receive the data defining the sequence and to process the data to generate predicted outputs that characterize how strongly the aptamer binds to the particular target molecule.
    Type: Grant
    Filed: January 24, 2020
    Date of Patent: June 6, 2023
    Assignee: Google LLC
    Inventors: Michelle Therese Hoerner Dimon, Marc Berndl, Marc Adlai Coram, Brian Trippe, Patrick F. Riley, Philip Charles Nelson
  • Patent number: 11664189
    Abstract: The present invention provides an apparatus of charged-particle beam e.g. an electron microscope comprising a plasma generator for selectively cleaning BSE detector. In various embodiments, the plasma generator is located between a sample stage and a sample table having one or more openings or holes. The plasma generator generates plasma and distributes or dissipates the plasma through the openings of the sample table toward and onto surface of the BSE detector. Cleaning contaminants on the surface of the BSE detector frequently and selectively with in-situ generated plasma can prevent the detectors from performance deterioration such as losing resolution and contrast in imaging at high levels of magnification.
    Type: Grant
    Filed: May 9, 2022
    Date of Patent: May 30, 2023
    Assignee: BORRIES PTE. LTD.
    Inventors: Zhongwei Chen, Xiaoming Chen, Daniel Tang, Liang-Fu Fan
  • Patent number: 11654153
    Abstract: The present invention relates to the design of a customized therapy for a subject with breast cancer based on the c-MAF expression level and the menopausal status of the subject. In some embodiments, the customized therapy comprises an agent for avoiding, treating or preventing bone degradation. In some embodiments, the agent for avoiding, treating or preventing bone degradation is zoledronic acid. In other embodiments, the agent is clodronate or denosumab.
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: May 23, 2023
    Assignee: INBIOMOTION S.L.
    Inventors: Walter Martin Gregory, Juan Carlos Tercero, Robert E. Coleman, Roger Gomis
  • Patent number: 11656197
    Abstract: A sequencing device is disclosed. The sequence device includes an array of conducting electrode pairs, each pair of electrodes comprising a source and a drain electrode arrangement separated by a nanogap, the electrode array deposited and patterned on a dielectric substrate; at least one transition metal dichalcogenide (TMD) layer disposed on each pair of electrodes, wherein the TMD layer connects each source and drain electrode within each pair, and bridges each nanogap of each pair of electrodes; and a dielectric masking layer disposed on the TMD layer and comprising at least one opening that defines an exposed TMD region, wherein the at least one opening is sized so as to allow a single biomolecule to fit therein and to attach on to the exposed TMD region. In embodiments of the disclosure, the TMD layer be a defective TMD layer.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: May 23, 2023
    Assignee: Roswell ME Inc.
    Inventors: Chulmin Choi, Sungho Jin, Barry L. Merriman, Paul Mola, Tim Geiser
  • Patent number: 11649485
    Abstract: The present disclosure relates to compositions and methods for generating capture probes on a substrate for identifying the location of analytes in a biological sample.
    Type: Grant
    Filed: March 25, 2021
    Date of Patent: May 16, 2023
    Assignee: 10x Genomics, Inc.
    Inventors: Yifeng Yin, Eswar Prasad Ramachandran Iyer, Zachary Bent, Stefania Giacomello, Meghan L. F. Frey, Alexander Gagnon, Erik Leonard Henrik Borgstrom
  • Patent number: 11648560
    Abstract: Provided herein, among other aspects, are methods and apparatuses for analyzing particles in a sample. In some aspects, the particles can be analytes, cells, nucleic acids, or proteins and can be contacted with a tag, partitioned into aliquots, detected by a ranking device, and isolated. The methods and apparatuses provided herein may include a microfluidic chip. In some aspects, the methods and apparatuses may be used to quantify rare particles in a sample, such as cancer cells and other rare cells for disease diagnosis, prognosis, or treatment.
    Type: Grant
    Filed: August 15, 2018
    Date of Patent: May 16, 2023
    Assignees: University of Washnington, Micareo Inc.
    Inventors: Daniel T. Chiu, Mengxia Zhao, Eleanor S. Shah, Perry G. Schiro, Hui Min Yu, Wei-Feng Fang, Jui-Lin Chen
  • Patent number: 11639928
    Abstract: The present disclosure provides methods of processing or analyzing a sample. A method for processing a sample may comprise hybridizing a probe molecule to a target region of a nucleic acid molecule (e.g., a ribonucleic acid (RNA) molecule), barcoding the probe-nucleic acid molecule complex, and performing extension, denaturation, and amplification processes. A method for processing a sample may comprise hybridizing first and second probes to adjacent or non-adjacent target regions of a nucleic acid molecule (e.g., an RNA molecule), linking the first and second probes to provide a probe-linked nucleic acid molecule, and barcoding the probe-linked nucleic acid molecule. One or more processes of the methods described herein may be performed within a partition, such as a droplet or well. One or more processes of the methods described herein may be performed on a cell, such as a permeabilized cell.
    Type: Grant
    Filed: February 24, 2022
    Date of Patent: May 2, 2023
    Assignee: 10X GENOMICS, INC.
    Inventors: Tarjei Sigurd Mikkelsen, Eswar Prasad Ramachandran Iyer, Andrew Kohlway, Luigi Jhon Alvarado Martinez, Katherine Pfeiffer, Andrew D. Price
  • Patent number: 11623012
    Abstract: The present invention relates to polypeptides which are covalently bound to aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of the Eph receptor tyrosine kinase A2 (EphA2). The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and dmg conjugates in preventing, suppressing or treating a disease or disorder characterised by overexpression of EphA2 in diseased tissue (such as a tumour).
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: April 11, 2023
    Assignee: BicycleRD Limited
    Inventors: Liuhong Chen, Silvia Pavan, Catherine Stace, Daniel Teufel, Katerine Van Rietschoten
  • Patent number: 11618922
    Abstract: Diagnostic biomarkers for diagnosing immune suppression/dysfunction. The diagnostic biomarkers are genes and/or transcripts that are up or down regulated compared to normal expression when a subject has been stressed either mentally and/or physically. The invention also relates to a method of detecting comprised or suppressed immune response in a subject by comparing certain diagnostic biomarkers in the subject to a control set of diagnostic biomarkers.
    Type: Grant
    Filed: October 20, 2014
    Date of Patent: April 4, 2023
    Assignee: The Government of the United States, as Represented by the Secretary of the Army
    Inventors: Seid Muhie, Marti Jett, Rasha Hammamieh
  • Patent number: 11607689
    Abstract: Described herein are systems relating to a continuous-flow instrument that includes all necessary components for digital droplet quantification without the need to introduce key reagents or collect and transfer droplets between stages of instrument operation. Digital quantification can proceed without any additional fluid or consumable handling and without exposing fluids to risk of external contamination.
    Type: Grant
    Filed: May 27, 2022
    Date of Patent: March 21, 2023
    Inventors: Cody Youngbull, Andrew Hatch, Andrew Larsen, Tathagata Ray, Matthew Underhill
  • Patent number: 11603555
    Abstract: In various embodiments methods of determining methylation of DNA are provided.
    Type: Grant
    Filed: June 14, 2016
    Date of Patent: March 14, 2023
    Assignee: CEPHEID
    Inventors: Edwin W. Lai, Andrew Kohlway, Reuel Vanatta, Russell Higuchi, Alexander Gall, Kriszten Kocmond
  • Patent number: 11603563
    Abstract: Provided is a method of predicting differentiation potential of undifferentiated iPS cells into cartilage cells. Provided is a genetic marker for predicting differentiation potential of undifferentiated iPS cells into cartilage cells. A method of predicting differentiation potential of undifferentiated iPS cells into cartilage cells based on gene expression data of the undifferentiated iPS cells. A method of predicting differentiation potential of undifferentiated iPS cells into cartilage cells by predicting differentiation potential of the iPS cells into neural crest cells (NC cells) based on gene expression data of the undifferentiated iPS cells.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: March 14, 2023
    Assignees: Shimadzu Corporation, Kyoto University
    Inventors: Makoto Watanabe, Taka-Aki Sato, Junya Toguchida
  • Patent number: 11597744
    Abstract: Disclosed are chiral phosphoramidite auxiliary compositions for diastereoselective synthesis of stereochemically enriched oligonucleotides, and nucleoside phosphoramidite compounds comprising the same. Exemplary structures of the chiral phosphoramidite auxiliary compositions include Formulas (IA) and (IB).
    Type: Grant
    Filed: July 2, 2018
    Date of Patent: March 7, 2023
    Inventors: Sukumar Sakamuri, Curt W. Bradshaw, Dingguo Liu, Laxman Eltepu
  • Patent number: 11598779
    Abstract: Methods for identifying and detecting potential disease specific biomarkers from biofluids. The methods involve in vivo administration of nanoparticles to a subject in a diseased state or incubating nanoparticles in a biofluid sample taken from a subject in a diseased state and analysis of the biomolecule corona formed on said nanoparticles. The methods distinguish between a healthy and diseased state in a subject, such as, for example, the presence of a tumor in a human subject.
    Type: Grant
    Filed: September 6, 2017
    Date of Patent: March 7, 2023
    Inventors: Kostas Kostarelos, Marilena Hadjidemetriou
  • Patent number: RE49774
    Abstract: The invention relates to methods for conducting solid-phase binding assays. One example is an assay method having improved analyte specificity where specificity is limited by the presence of non-specific binding interactions.
    Type: Grant
    Filed: February 11, 2021
    Date of Patent: January 2, 2024
    Inventors: Eli N. Glezer, Sudeep Kumar, Pankaj Oberoi, George Sigal, Michael Tsionsky